Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509297 | 0.89 | KDM4E (0.54) | KDM4EALDH1A1GAAPDE3ASMN1; SMN2 | |
| SCHEMBL509858 | 0.85 | SYK (0.56) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3825399 | 0.77 | NPC1 (0.56) | KDM4EALDH1A1GAANPC1RAB9A | |
| SCHEMBL3829219 | 0.76 | NPC1 (0.51) | KDM4EALDH1A1GAASMN1; SMN2NPC1 | |
| SCHEMBL509124 | 0.76 | NPC1 (0.47) | ALDH1A1SMN1; SMN2HPGDNPC1RAB9A | |
| SCHEMBL510204 | 0.74 | RAD52 (0.49) | KDM4EALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL509097 | 0.74 | XDH (0.50) | ALDH1A1SMN1; SMN2NPC1RAB9AADORA2A | |
| SCHEMBL26075525 | 0.74 | ESR1 (0.54) | KDM4EALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL508360 | 0.73 | SYK (0.56) | KDM4EALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL509138 | 0.73 | SCN2A (0.48) | KDM4EALDH1A1SMN1; SMN2HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532020-B | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives | REXAHN PHARMACEUTICALS INC | 2015-02-25 | — | — | CN | disclosed |
| US-8314123-B2 | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| CN-102532020-A | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS INC | 2012-07-04 | — | — | CN | disclosed |
| EP-2423196-A1 | 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof | Rexahn Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| CN-101573337-B | 5, 6 or 7-substituted-3- (hetero) aryl-isoquinolinamine derivatives as antitumor agents | REXAHN PHARMACEUTICALS, INC. (US) | 2012-02-08 | — | — | CN | disclosed |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034829-B2 | e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. | REXAHN PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| CN-101573337-A | 5, 6 or 7-substituted-3- (hetero) aryl-isoquinolinamine derivatives as antitumor agents | REXAHN PHARMACEUTICALS INC (US) | 2009-11-04 | — | — | CN | disclosed |
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | FANCD2, NRAS, CCND2 | KDM4E 2109/4885ALDH1A1 997/4885GAA 1791/4885 |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | FANCD2, NRAS, CCND2 | KDM4E 2109/4885ALDH1A1 997/4885GAA 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.